Pipeline
Research | Pre-clinical development | Phase I | Phase II |
---|---|---|---|
ADC-1013* (CD40)
|
|||
ATOR-1015 (OX40 - CTLA-4)
|
|||
ATOR-1017 (4-1BB)
|
|||
ALG.APV-527* (4-1BB - 5T4)
|
|||
(TNFRSF – ND)
|

Alligators Bioscience's portfolio comprise the drug candidates mitazalimab, ATOR-1017 and ALG.APV-527, as well as the drug concept Neo-X-Prime™, all of which are intended for the treatment of metastatic cancers. The project AC101 (HLX22) is run by a partner, the Chinese company Shanghai Henlius Biotech Inc., who are responsible for financing and operating its clinical development.